¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"loss cone"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bifurcation cone
    ºÐ±â¿ø»Ô
  • cone
    ¿ø»Ô, ¿øÃß
  • cone biopsy
    ¿ø»Ô»ý°Ë
  • cone cell
    ¿ø»Ô¼¼Æ÷
  • cone cell layer
    ¿ø»Ô¼¼Æ÷Ãþ, ¿øÃß¼¼Æ÷Ãþ
  • cone down
    Á¶»ç¿µ¿ªÃà¼Ò
  • cone down technique
    Á¶»ç¿µ¿ªÃà¼Ò¹ý
  • cone monochromatism
    ¿ø»Ô¼¼Æ÷¿ÏÀü»ö¸Í, Ãßü´Ü»öÇü»ö°¢
  • cone of light
    ±¤Ã߸é
  • cone pedicle
    ¿ø»Ô¼¼Æ÷»Ñ¸®
  • cone pigment
    ¿ø»Ô»ö¼Ò
  • fertilization cone
    ¼öÁ¤¿ø»Ô
  • growth cone
    ¼ºÀå¿ø»Ô
  • ocular cone
    ½Ã°¢¿ø»Ô
  • pressure cone
    ¾Ð¹Ú¿ø»Ô
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cone
    ¿ø»Ô
  • loss
    »ó½Ç
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
  • blood loss
    ½ÇÇ÷, Ç÷¾×»ó½Ç
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • loss of short-term variability
    ´Ü±âº¯µ¿¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bifurcation cone
    ºÐ±â¿ø»Ô
  • cone biopsy
    ¿ø»Ô»ý°Ë, ¿øÃß»ý°Ë
  • cone
    ¿ø»Ô
  • cone cell
    ¿ø»Ô¼¼Æ÷
  • cone monochromatism
    Ãßü´Ü»öÇü»ö°¢, ¿ø»Ô¼¼Æ÷¿ÏÀü»ö¸Í
  • cone pedicle
    ¿ø»Ô¼¼Æ÷»Ñ¸®
  • cone pigment
    ¿ø»Ô»ö¼Ò
  • cone cell layer
    ¿ø»Ô¼¼Æ÷Ãþ
  • cone down technique
    Á¶»ç¿µ¿ªÃà¼Ò¹ý
  • fertilization cone
    ¼öÁ¤¿ø»Ô
  • growth cone
    ¼ºÀå¿ø»Ô
  • ocular cone
    ½Ã°¢¿ø»Ô
  • pressure cone
    ¾Ð¹Ú¿ø»Ô
  • visual cone
    (¢¡ocular cone) ½Ã°¢¿ø»Ô
  • abrasion loss
    ¸¶¸ê·®, ¸¶¸ð·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Cone pigments
    »ö¼Ò(ßäáÈ)
  • arterial cone
    µ¿¸Æ¿ø»Ô
  • gingival cone
    Ä¡Àº¿ø»Ô.
  • green cone
    ³ì»öÃßü
  • growth cone
    ¼ºÀå¿ø»Ô
  • hair cone
    ¸ð(Ù¾)¿ø»Ô.
  • hard clavus => hard cone
    °æ¿ì¾È
  • pressure cone
    ¾Ð¹Ú¿ø»Ô(äâÚÞ¡­)
  • red cone
    Àû»öÃßü
  • Heat loss
    ¿­¼Õ½Ç(æðáßã÷)
  • NIHL [=noise induced hearing loss]
    ¼ÒÀ½¼º ³­Ã»
  • abrasion loss
    ¸¶¸ê·®(¸¶¸ê¾ç).
  • functional hearing loss
    ±â´É(¼º) ³­Ã»
  • hearing loss
    °¨°¢½Å°æ(¼º) ³­Ã»
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç, û·ÂÀå¾Ö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • arterial cone
    µ¿¸Æ¿ø»Ô
  • bifurcation cone
    ºÐ±â ¿ø»Ô.
  • blue cone
    û»öÃßü
  • cone
    ÀÏ¹Ý ¿ø»Ô, Ãßü(õÞô÷).
  • cone
    ¿øÃß(ê­õÞ), ¿ø»Ô, ÀÏ¹Ý ¿ø»Ô, Ãßü(õÞô÷).
  • cone
    Á¶»çÅë, Á¶»ç¿ø»Ô
  • cone
    Ãßü
  • cone biopsy
    ¿øÃß»ý°Ë
  • cone cell
    ¿ø»Ô¼¼Æ÷, Ãß»óü¼¼Æ÷(¡­á¬øà).
  • cone cell
    ¿ø»Ô¼¼Æ÷
  • cone cell layer
    ¿ø»Ô¼¼Æ÷Ãþ, ÃßüÃþ.
  • cone down technique
    Á¶»ç¿µ¿ªÃà¼Ò¹ý
  • cone dystrophy
    ÃßüÀÌ¿µ¾ç(Áõ)
  • cone monochromatism
    Ãßü´Ü»öÇü»ö°¢, Ãßü¿ÏÀü»ö¸Í
  • cone of light
    ±¤Ãß(¸é)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Arterial cone
    µ¿¸Æ¿ø»Ô
    [¿¾ ¿ë¾î] µ¿¸Æ¿øÃß
  • Fertilization cone
    ¼öÁ¤¿ø»Ô
    [¿¾ ¿ë¾î] ¼öÁ¤¿øÃß
  • Elastic cone [Cricovocal membrane]
    ź·Â¿ø»Ô [¹ÝÁö¼º´ë¸·]
    [¿¾ ¿ë¾î] ź¼º¿øÃß
  • Ectoplacental cone
    Źݹۿø»Ô (DzŹÝ)
    [¿¾ ¿ë¾î] ÀüŹÝ
  • Cone pedicle
    ¿ø»Ô¼¼Æ÷¹ß
    [¿¾ ¿ë¾î] Ãß»óü¼ÒÁ·
  • Growth cone
    ¼ºÀå¿ø»Ô
    [¿¾ ¿ë¾î] ¼ºÀå¿øÃß
  • Cone cell
    ¿ø»Ô¼¼Æ÷
    [¿¾ ¿ë¾î] Ãß»óü½Ã¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • coincidence loss
    µ¿½Ã¼Õ½Ç(ÔÒãÁáßã÷)
  • cone
    ¿øÃß¼¼Æ÷(ê­õÞá¬øà)
  • cone threshold
    ¿øÃß¼¼Æ÷¿ªÄ¡(ê­õÞá¬øàæ´ö·)
  • counting loss
    "°èÃø ¼Õ½Ç(ͪö´áßã÷), (ÔÒ) coincidence loss"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cone
    ¿ø»Ô, Ãßü
  • central hearing loss
    ÁßÃß¼º û·Â»ó½Ç, ÁßÃß¼º ³­Ã»
  • energy loss
    ¿¡³ÊÁö¼Õ½Ç
  • hearing loss
    û°¢¼Õ½Ç
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • sensorineural hearing loss
    °¨°¢½Å°æ¼º³­Ã»
  • signal loss
    ½ÅÈ£¼Ò½Ç
  • weight loss
    üÁß°¨¼Ò, °¨·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IDA   1) Imino-Diacetic Acid
  2) Iron Deficiency Anemia
   &nb...
BCP basic calcium phosphate; birth control pill; blue cone pigment; Blue Cross Plan; bromcresol purple
CBBM color blindness, blue mono-cone-monochromatic type
CRD carbohydrate-recognition domain; chronic renal disease; chronic respiratory disease; child restraint...
CSE clinical-symptom/self-evaluation [questionnaire]; cone-shaped epiphysis; conventional spin-echo; cro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
GCP Growth cone particle
prcd Progressive rod-cone degeneration
CRD cone-rod dystrophy
EPC ectoplacental cone
GC growth cone
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • accessory cone
    º¸Á¶ ÄÜ
  • carious cone
    ¿ì½Ä ¿øÃß
  • cone cell
    ¿ø»Ô ¼¼Æ÷, Ãß»óü ¼¼Æ÷, ¿øÃß ¼¼Æ÷
    ôÃßµ¿¹°ÀÇ ¸Á¸·ÀÇ °¡Àå ¾ÈÂÊ¿¡ ÀÖ´Â ½Ã¼¼Æ÷ÀÇ ÀÏÁ¾. Ãßü ¼¼Æ÷, Ãß»óü ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ½Ã¼¼Æ÷´Â ±× ÇüÅÂ¿Í ±â´É»ó¿¡ µû¶ó ¿øÃß ¼¼Æ÷¿Í °£»ó ¼¼Æ÷ÀÇ 2Á¾À¸·Î ±¸º°µÈ´Ù. ¿øÃß ¼¼Æ÷´Â ºñ±³Àû ¹àÀº °÷¿¡¼­ ¹°Ã¼¸¦ º¸´Â ÀÏ, »öÀ» ½Äº°
  • cone monochromatism
    Ãßü ´Ü»öÇü »ö°¢, Ãßü ¿ÏÀü »ö¸Í
  • cone-cut
    ºÎºÐ »ó
  • inverted cone bur
    µµ¿ø ÃßÇü ¹Ù
    ¹ÙÀÇ Á÷°æÀÌ À§º¸´Ù ¹ØÀÌ ³ÐÀº ÇüÅ·Π»ý±ä »èÇÕ¿ë ¹Ù.
  • Politzer's luminous cone
    Æú¸®Ã³ ±¤Ãß
    °í¸· ÇϺÎÀÇ ±¤ÅÃÀÌ ÀÖ´Â »ï°¢ ºÎÀ§.
  • Prothero cone theory
    ÇÁ·Îµ¥·Î ÄÜ ¼³
  • sarcoplasmic cone
    ±ÙÇüÁú ÆØ´ë
  • abrasion loss
    ¸¶¸ê ·®
    ¸¶¸ð°¡ µÇ¾î ¼Õ½ÇµÈ ¾ç.
  • blood loss
    ½ÇÇ÷
  • breathing loss
    È£Èí ¼Õ½Ç
  • energy loss
    ¿¡³ÊÁö ¼Õ½Ç
  • evaporation loss
    Áõ¹ß ¼Õ½Ç
  • familial progressive sensorineural hearing loss
    °¡Á·¼º ÁøÇ༺ °¨°¢ ½Å°æ¼º ³­Ã»
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
loss cone In a magnetic mirror machine, particles with a large velocity parallel to the magneitc field and a small velocity perpendicular to the field will be able to escape past the magnetic mirror (see magnetic mirror). In that case the velocity distribution function (see distribution function) will be almost zero in the region of velocity space that allows particles to escape. The shape of that region (in a velocity space diagram with parallel velocity and perpendicular velocity as the axes) is a cone. When a particle undergoes a collision, its velocity gets somewhat randomised. Particles that are scattered into that cone are lost very quickly (in one mirror bounce time). Thus it is called a loss cone. Because of the loss cone, the theoretical maximum particle confinement time of a magnetic mirror machine can be only a few times the particle collision time, this is generally seen as a showstopper for mirror-based fusion research.
(09 Oct 1997)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
drift cyclotron loss cone instabilities (DCLC) This is an electrostatic microinstability (frequencies at harmonics of the ion cyclotron frequency) which is of major concern in small mirror devices. Mode is driven by radial gradients in the electron density, and causes loss of ions due to non-conservation of magnetic moment (see adiabatic invariant) as they interact with the mode, and are dispersed in velocity space into the loss cone. Stabilisation is accomplished by increasing the plasma size and by partially filling the loss cone with a continuous extermal warm plasma stream.
(09 Oct 1997)
alveolar bone loss The resorption of bone in the supporting structures of the maxilla or mandible as a result of periodontal disease.
(12 Dec 1998)
axon loss polyneuropathy A type of polyneuropathy in which axon degeneration is the sole/predominant feature; many aetiologies, particularly toxic and metabolic; on nerve conduction studies, affects amplitudes of the responses, but does not cause conduction slowing or block.
Synonym: axonal polyneuropathy.
(05 Mar 2000)
blood loss, surgical Loss of blood during surgery.
(12 Dec 1998)
Parallel Electron Energy Loss Spectroscopy <technique> Electron energy loss spectroscopy analyses the inelastically scattered electrons present in the beam after it has been transmitted through the sample. An electron energy loss spectrum typically consists of a monatomic decreasing background on which are superimposed a number of peaks. Each peak is characteristic of the scattering process that has occurred in the sample. The peaks can be used to obtain information about the chemical composition and electronic structure of the sample. Electron energy loss spectra are acquired typically in a magnetic sector spectrometer located under the camera chamber of the transmission electron microscope. Spatial resolution is typically limited by the minimum probe diameter of the microscope. Electron energy loss spectroscopy tends to be complimentary to EDS in that it can be used to analyse very thin samples of low Z materials.
Acronym: PEELS
(05 Aug 1998)
periodontal attachment loss Loss or destruction of periodontal tissue caused by periodontitis or other destructive periodontal diseases or by injury during instrumentation. Attachment refers to the periodontal ligament which attaches to the alveolar bone. It has been hypothesised that treatment of the underlying periodontal disease and the seeding of periodontal ligament cells enable the creating of new attachment.
(12 Dec 1998)
water loss, insensible Loss of water by diffusion through the skin and by evaporation from the respiratory tract. It is so called because we do not know that we are actually losing water at the time that it is leaving the body. (guyton, textbook of medical physiology, 8th ed, p274)
(12 Dec 1998)
weight loss Decrease in existing body weight.
(12 Dec 1998)
conductive hearing loss <otolaryngology> A form of deafness that results from a blockage of the ear canal or dysfunction of the ossicles or eardrum (sound collecting apparatus).
In conductive hearing loss the auditory nerve is normal, but there exists a physical problem with the sound collecting apparatus.
(05 Jan 1998)
hair loss Hair loss may be associated with aging, hormones (androgens) or genetic predisposition. The pattern of baldness in women is different from that of men. In women there is thinning of the hair all over the scalp, but the frontal hairline is maintained. The hair loss is usually permanent. Treatment has been successful with topical minoxidil in some cases.
(13 Nov 1997)
hearing loss, bilateral Partial hearing loss in both ears.
(12 Dec 1998)
hearing loss, central Hearing loss due to central nervous system disease, anywhere in the auditory pathways from the cochlear nucleus of the pons to the auditory cortex.
(12 Dec 1998)
hearing loss, conductive Hearing loss due to interference with the acoustic transmission of sound to the cochlea. The interference is in the outer or middle ear.
(12 Dec 1998)
hearing loss, functional Hearing loss without a physical basis.
(12 Dec 1998)
hearing loss, high-frequency Hearing loss in frequencies above 1000 hertz.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • be at a loss
    ºÒÈ®½ÇÇÑ »óÅ¿¡ ÀÖ´Ù
  • cone
    ¿øÃßÇü
  • loss
    ºÐ½Ç
  • cone
    ¿ø»Ô;¿øÃßÇü (ÀǰÍ);ÆøÇ³ °æº¸±¸;(¾ÆÀ̽ºÅ©¸²ÀÇ)ÄÜ;÷ºÀ;È­»ê ¿ø»Ô;¹æ¿ï¿­¸Å;±¸°ú;¼Ö¹æ¿ï;³ª»çÁ¶°³;¿ø»Ô²Ã·Î ¸¸µé´Ù;(¿øÃßÇüÀ¸·Î)ºñ½ºµëÈ÷ ÀÚ¸£´Ù;±¸°ú¸¦ ¸Î´Ù;¿øÃßÇüÀ» ÀÌ·ç´Ù
  • consequential loss insurance
    °£Á¢ ¼ÕÇØ º¸Çè
  • dead loss
    Àü¼Õ
  • fir cone
    Àü³ª¹« ¿­¸Å
  • friction loss
    ¸¶Âû¼Õ½Ç
  • icecream cone
    ¾ÆÀ̽ºÅ©¸²À» ´ã´Â ¿ø»Ô²Ã ¿þÀÌÆÛ(wafer)
  • loss
    ¼Õ½Ç;»ó½Ç;¼ÕÇØ;½ÇÆÐ;ÆÐ¹è;¼Ò¸ð;at a ~ °ï¶õÇÏ¿©;¾î¿ ÁÙ ¸ô¶ó¼­
  • loss leader
    Ư¸Åǰ
  • nose cone
    (·ÎÄϵîÀÇ)¿øÃßÇü µÎºÎ)
  • pine cone
    ¼Ö¹æ¿ï
  • tail cone
    Å×ÀÏÄÜ(±âü ²¿¸® ºÎºÐÀÇ ¿øÃßÇü ±¸Á¶¹°)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á